Research ArticleSystemic Sclerosis

Esophageal Dilation and Other Clinical Factors Associated With Pulmonary Function Decline in Patients With Systemic Sclerosis

Kimberly Showalter, Aileen Hoffmann, Carrie Richardson, David Aaby, Jungwha Lee, Jane Dematte, Rishi Agrawal, Hatice Savas, Xiaoping Wu, Rowland W. Chang and Monique Hinchcliff
The Journal of Rheumatology December 2021, 48 (12) 1830-1838; DOI: https://doi.org/10.3899/jrheum.210533

REFERENCES

  1. 1.↵
    1. Christmann RB,
    2. Wells AU,
    3. Capelozzi VL,
    4. Silver RM
    . Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin Arthritis Rheum 2010;40:241–9.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Wells AU
    . Interstitial lung disease in systemic sclerosis. Presse Med 2014;10 Pt 2:e329–43.
    OpenUrl
  3. 3.↵
    1. Winstone TA,
    2. Assayag D,
    3. Wilcox PG,
    4. Dunne JV,
    5. Hague CJ,
    6. Leipsic J, et al
    . Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest 2014;146:422–36.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Liu X,
    2. Mayes MD,
    3. Pedroza C,
    4. Draeger HT,
    5. Gonzalez EB,
    6. Harper BE, et al
    . Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis? Arthritis Care Res 2013;65:1375–80.
    OpenUrlCrossRef
  5. 5.↵
    1. Assassi S,
    2. Sharif R,
    3. Lasky RE,
    4. McNearney TA,
    5. Estrada YMRM,
    6. Draeger H, et al; GENISOS Study Group
    . Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther 2010;12:R166.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Sjogren RW
    . Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994;37:1265–82.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Pitrez EH,
    2. Bredemeier M,
    3. Xavier RM,
    4. Capobianco KG,
    5. Restelli VG,
    6. Vieira MV, et al
    . Oesophageal dysmotility in systemic sclerosis: comparison of HRCT and scintigraphy. Br J Radiol 2006; 79:719–24.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Marie I,
    2. Dominique S,
    3. Levesque H,
    4. Ducrotte P,
    5. Denis P,
    6. Hellot MF, et al
    . Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 2001;45:346–54.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Richardson C,
    2. Agrawal R,
    3. Lee J,
    4. Almagor O,
    5. Nelson R,
    6. Varga J, et al
    . Esophageal dilatation and interstitial lung disease in systemic sclerosis: a cross-sectional study. Semin Arthritis Rheum 2016;46:109–14.
    OpenUrl
  10. 10.↵
    1. Hoffmann A,
    2. Lee J,
    3. Ma M,
    4. Agrawal R,
    5. Chang RW,
    6. Richardson C, et al
    . Comment on “esophageal dilatation and interstitial lung disease in systemic sclerosis: a cross-sectional study”. Semin Arthritis Rheum 2016;46:e11–2.
    OpenUrl
  11. 11.↵
    1. Johnson DA,
    2. Drane WE,
    3. Curran J,
    4. Cattau EL, Jr.,
    5. Ciarleglio C,
    6. Khan A, et al
    . Pulmonary disease in progressive systemic sclerosis. A complication of gastroesophageal reflux and occult aspiration? Arch Intern Med 1989;149:589–93.
    OpenUrl
  12. 12.↵
    1. Lock G,
    2. Pfeifer M,
    3. Straub RH,
    4. Zeuner M,
    5. Lang B,
    6. Scholmerich J, et al
    . Association of esophageal dysfunction and pulmonary function impairment in systemic sclerosis. Am J Gastroenterol 1998;93:341–5.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Lee JS,
    2. Collard HR,
    3. Raghu G,
    4. Sweet MP,
    5. Hays SR,
    6. Campos GM, et al
    . Does chronic microaspiration cause idiopathic pulmonary fibrosis? Am J Med 2010;123:304–11.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Raghu G,
    2. Yang ST,
    3. Spada C,
    4. Hayes J,
    5. Pellegrini CA
    . Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest 2006;129:794–800.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. van den Hoogen F,
    2. Khanna D,
    3. Fransen J,
    4. Johnson SR,
    5. Baron M,
    6. Tyndall A, et al
    . 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737–47.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Galie N,
    2. Hoeper MM,
    3. Humbert M,
    4. Torbicki A,
    5. Vachiery JL,
    6. Barbera JA, et al; ESC Committee for Practice Guidelines (CPG)
    . Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493–537.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Kazerooni EA,
    2. Martinez FJ,
    3. Flint A,
    4. Jamadar DA,
    5. Gross BH,
    6. Spizarny DL, et al
    . Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997;169:977–83.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Hankinson JL,
    2. Odencrantz JR,
    3. Fedan KB
    . Spirometric reference values from a sample of the general U.S. Population. Am J Respir Crit Care Med 1999;159:179–87.
    OpenUrlCrossRef
  19. 19.↵
    1. Macintyre N,
    2. Crapo RO,
    3. Viegi G,
    4. Johnson DC,
    5. van der Grinten CP,
    6. Brusasco V, et al
    . Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005;26:720–35.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Tashkin DP,
    2. Roth MD,
    3. Clements PJ,
    4. Furst DE,
    5. Khanna D,
    6. Kleerup EC, et al; Sclerodema Lung Study II Investigators
    . Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016;4:708–19.
    OpenUrl
  21. 21.↵
    1. Goh NS,
    2. Hoyles RK,
    3. Denton CP,
    4. Hansell DM,
    5. Renzoni EA,
    6. Maher TM, et al
    . Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol 2017;69:1670–8.
    OpenUrlPubMed
  22. 22.
    1. Goh NS,
    2. Desai SR,
    3. Anagnostopoulos C,
    4. Hansell DM,
    5. Hoyles RK,
    6. Sato H, et al
    . Increased epithelial permeability in pulmonary fibrosis in relation to disease progression. Eur Respir J 2011;38:184–90.
    OpenUrlAbstract/FREE Full Text
  23. 23.
    1. Bouros D,
    2. Wells AU,
    3. Nicholson AG,
    4. Colby TV,
    5. Polychronopoulos V,
    6. Pantelidis P, et al
    . Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002;165:1581–6.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. du Bois RM,
    2. Weycker D,
    3. Albera C,
    4. Bradford WZ,
    5. Costabel U,
    6. Kartashov A, et al
    . Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011;184:1382–9.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Kafaja S,
    2. Clements PJ,
    3. Wilhalme H,
    4. Tseng CH,
    5. Furst DE,
    6. Kim GH, et al
    . Reliability and minimal clinically important differences of forced vital capacity: results from the scleroderma lung studies (SLS-I and SLS-II). Am J Respir Crit Care Med 2018;197:644–52.
    OpenUrlPubMed
  26. 26.↵
    1. Khanna D,
    2. Mittoo S,
    3. Aggarwal R,
    4. Proudman SM,
    5. Dalbeth N,
    6. Matteson EL, et al
    . Connective tissue disease-associated interstitial lung diseases (CTD-ILD) – report from OMERACT CTD-ILD working group. J Rheumatol 2015;42:2168–71.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Savarino E,
    2. Bazzica M,
    3. Zentilin P,
    4. Pohl D,
    5. Parodi A,
    6. Cittadini G, et al
    . Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med 2009;179:408–13.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Winstone TA,
    2. Hague CJ,
    3. Soon J,
    4. Sulaiman N,
    5. Murphy D,
    6. Leipsic J, et al
    . Oesophageal diameter is associated with severity but not progression of systemic sclerosis-associated interstitial lung disease. Respirology 2018;23:921–6.
    OpenUrl
  29. 29.↵
    1. Steen V
    . Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 2003;62:97–9.
    OpenUrlFREE Full Text
  30. 30.↵
    1. Steele R,
    2. Hudson M,
    3. Lo E,
    4. Baron M, Canadian Scleroderma Research Group
    . Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res 2012;64:519–24.
    OpenUrlCrossRef
  31. 31.↵
    1. Suliman YA,
    2. Dobrota R,
    3. Huscher D,
    4. Nguyen-Kim TD,
    5. Maurer B,
    6. Jordan S, et al
    . Brief report: pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease. Arthritis Rheumatol 2015;67:3256–61.
    OpenUrl
  32. 32.↵
    1. Vonk MC,
    2. van Die CE,
    3. Snoeren MM,
    4. Bhansing KJ,
    5. van Riel PL,
    6. Fransen J, et al
    . Oesophageal dilatation on high-resolution computed tomography scan of the lungs as a sign of scleroderma. Ann Rheum Dis 2008;67:1317–21.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Tashkin DP,
    2. Elashoff R,
    3. Clements PJ,
    4. Goldin J,
    5. Roth MD,
    6. Furst DE, et al; Scleroderma Lung Study Research Group
    . Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655–66.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Lee JS,
    2. Collard HR,
    3. Anstrom KJ,
    4. Martinez FJ,
    5. Noth I,
    6. Roberts RS, et al; IPFnet Investigators
    . Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med 2013;1:369–76.
    OpenUrl
  35. 35.↵
    1. Lee JS,
    2. Ryu JH,
    3. Elicker BM,
    4. Lydell CP,
    5. Jones KD,
    6. Wolters PJ, et al
    . Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:1390–4.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Distler O,
    2. Highland KB,
    3. Gahlemann M,
    4. Azuma A,
    5. Fischer A,
    6. Mayes MD, et al; SENSCIS Trial Investigators
    . Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 2019;380:2518–28.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Tashkin DP,
    2. Volkmann ER,
    3. Tseng CH,
    4. Kim HJ,
    5. Goldin J,
    6. Clements P, et al
    . Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. Ann Rheum Dis 2016;75:374–81.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Caron M,
    2. Hoa S,
    3. Hudson M,
    4. Schwartzman K,
    5. Steele R
    . Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease. Eur Respir Rev 2018;27:170102.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Frech TM,
    2. Shanmugam VK,
    3. Shah AA,
    4. Assassi S,
    5. Gordon JK,
    6. Hant FN, et al
    . Treatment of early diffuse systemic sclerosis skin disease. Clin Exp Rheumatol 2013;2 Suppl 76:166–71.
    OpenUrl
  40. 40.↵
    1. Minier T,
    2. Guiducci S,
    3. Bellando-Randone S,
    4. Bruni C,
    5. Lepri G,
    6. Czirjak L, et al; EUSTAR co-workers
    . Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis 2014;73:2087–93.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Bookmark this article

Jump to section

Keywords

BIOMARKERS
gastrointestinal disease
INTERSTITIAL LUNG DISEASE
SYSTEMIC SCLEROSIS

Keywords